Could two weeks of radiation be enough for breast cancer?
NCT ID NCT04175210
First seen May 23, 2026 · Last updated Jun 23, 2026 · Updated 4 times
Summary
This phase 3 trial compares a standard 3-week radiation course to an experimental 2-week course for women with early-stage breast cancer. About 400 participants who had lumpectomy will receive whole breast radiation plus an extra boost to the tumor site. The study checks if the shorter schedule causes similar side effects and controls cancer just as well.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Brooklyn Methodist Hospital - NewYork Presbyterian
New York, New York, 11215, United States
-
New York Presbyterian Hospital - Queens
New York, New York, 11355, United States
-
New York Presbyterian Hospital at Lower Manhattan Cancer Center
New York, New York, 10007, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
radiation therapy
What this could lead to
If successful, this could offer a shorter, more convenient radiation schedule for early breast cancer patients without compromising outcomes.
What could go wrong
This is a non-inferiority trial, so it aims to show the shorter course is not worse, not better. Results may not apply to all breast cancer types or stages.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.